NRG1: An Emerging Tumor Agnostic Target

Download All

Gain expert insight into the emerging role of NRG1 fusions as rare oncogenic drivers in a variety of solid tumors and learn about the targeted therapies in development from expert commentaries, a text-based module, and a downloadable slideset.

person default
Maria E. Arcila, MD
person default
Ryma Benayed, PhD
Stephen V. Liu, MD
Joshua Sabari, MD

Expert-Authored Online Activity

Learn how experts detect and treat NRG1 fusion–positive solid tumors in this interactive text module with expert perspectives from Stephen V. Liu, MD, and Ryma Benayed, PhD, on applying emerging research to biomarker testing and treatment strategies for patients with NRG1 fusion–driven cancers.

person default Ryma Benayed, PhD Stephen V. Liu, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: February 2, 2022 Expired: February 1, 2023

ClinicalThought

Read this commentary from Maria E. Arcila, MD, on the recommendations for testing for NRG1 fusions in patients with solid tumors.

person default Maria E. Arcila, MD Released: November 16, 2021

Expert commentary by Joshua Sabari, MD, on the role of NRG1 fusions in solid tumors and the emerging targeted therapies for patients harboring this oncogenic alteration.

Joshua Sabari, MD Released: February 28, 2022

Downloadable Slideset

Review this slideset on applying emerging research to biomarker testing and treatment strategies for patients with NRG1 fusion–driven cancers by Stephen V. Liu, MD, and Ryma Benayed, PhD.

person default Ryma Benayed, PhD Stephen V. Liu, MD Released: February 2, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

In partnership with
Supported by an educational grant from
Elevation Oncology, Inc.

Clinical Care Options (CCO): expert opinions from Drs Stephen Liu, Maria Arcila, Dr. Ryma Benayed on testing and targeting NRG1 fusions

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings